Kawakami Takeshi, Yamazaki Kentaro
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-0934, Japan.
Cancers (Basel). 2024 Apr 30;16(9):1747. doi: 10.3390/cancers16091747.
Human epidermal receptor (HER) 2-positive advanced gastric cancer is one of the major subtypes of gastric cancer, accounting for ~20% of all cases. Although combination therapy with trastuzumab and chemotherapy provides meaningful survival benefit, clinical trials targeting HER2 have failed to demonstrate clinical benefits in first- or subsequent-line treatment. Trastuzumab deruxtecan, an antibody-drug conjugate, has shown positive results even in later-line treatment and has become new standard treatment. In first-line therapy, combination therapy with pembrolizumab and trastuzumab plus chemotherapy demonstrated a dramatic response rate. Therefore, the FDA rapidly approved it without waiting for the results of survival time. The emergence of combination therapy including immunotherapy with HER2-targeting agents and the development of HER2 targeting agents with or without immunotherapy have been advancing for treating HER2-positive gastric cancer. In this review, we will discuss the current status of treatment development and future perspectives for HER2-positive gastric cancer.
人表皮受体（HER）2阳性晚期胃癌是胃癌的主要亚型之一，约占所有病例的20%。尽管曲妥珠单抗联合化疗可带来显著的生存获益，但针对HER2的临床试验在一线或后续治疗中均未显示出临床益处。抗体药物偶联物曲妥珠单抗德曲妥珠单抗即使在后续治疗中也显示出阳性结果，并已成为新的标准治疗方法。在一线治疗中，帕博利珠单抗联合曲妥珠单抗加化疗的联合治疗显示出显著的缓解率。因此，美国食品药品监督管理局（FDA）未等待生存时间结果就迅速批准了该疗法。包括HER2靶向药物免疫治疗的联合疗法的出现以及有或无免疫治疗的HER2靶向药物的开发一直在推进，用于治疗HER2阳性胃癌。在本综述中，我们将讨论HER2阳性胃癌治疗进展的现状和未来前景。
